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Objective: There are few guidelines for clinical trials of interventions for prevention of post-
traumatic osteoarthritis (PTOA), reflecting challenges in this area. An international multi-
disciplinary expert group including patients was convened to generate points to consider for 
the design and conduct of interventional studies following acute knee injury. 
Design: An evidence review on acute knee injury interventional studies to prevent PTOA was 
presented to the group, alongside overviews of challenges in this area, including potential 
targets, biomarkers and imaging. Working groups considered pre-identified key areas: 
eligibility criteria and outcomes, biomarkers, injury definition and intervention timing 
including multi-modality interventions. Consensus agreement within the group on points to 
consider was generated and is reported here after iterative review by all contributors. 
Results: The evidence review identified 37 studies. Study duration and outcomes varied 
widely and 70% examined surgical interventions. Considerations were grouped into 3 areas: 
justification of inclusion criteria including the classification of injury and participant age (as 
people over 35 may have pre-existing OA); careful consideration in the selection and timing 
of outcomes or biomarkers; definition of the intervention(s)/comparator(s) and the 
appropriate time-window for intervention (considerations may be particular to intervention 
type). Areas for further research included demonstrating the utility of patient-reported 
outcomes, biomarkers and imaging outcomes from ancillary/cohort studies in this area, and 
development of surrogate clinical trial endpoints that shorten the duration of clinical trials 
and are acceptable to regulatory agencies.  
Conclusions: These considerations represent the first international consensus on the 
conduct of interventional studies following acute knee joint trauma.  
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Running headline: Considerations for knee injury studies  
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Introduction 1 
Osteoarthritis (OA) pathologically represents a continuum from risk exposure, to molecular 2 
changes and structural changes with associated pain, which for some people progresses to 3 
the need for joint replacement. Detection and treatment of those at high risk of OA could 4 
enable effective interventions before any major structural damage has occurred or before 5 
pain becomes chronic, that is at a pre-radiographic or even pre-symptomatic stage. Such 6 
intervention would be comparable to current early management of diabetes, cardiovascular 7 
disease, osteoporosis or pre-rheumatoid arthritis.  8 
Joint injury remains one of the biggest risk factors for OA. In Sweden, approximately 80/100 9 
000 people per year experience anterior cruciate ligament (ACL) rupture; in the U.S. there 10 
are 252,000 ACL injuries per year(1, 2). 50% of people with significant knee joint injuries 11 
such as ACL rupture and/or acute meniscal tear subsequently develop symptomatic 12 
radiographic OA within 10 years, so-called post-traumatic OA (PTOA)(3); at least 33% with 13 
acute ACL rupture will have MRI-defined whole joint OA after 5 years(4). PTOA is thought to 14 
comprise around 12% of all OA, although its incidence appears to be increasing(5, 6). 15 
However, there are no specific guidelines for clinical trials which seek to measure the effect 16 
of interventions for prevention of OA after an injury(7, 8). There are a number of challenges 17 
in study design specific to this area, especially the potentially long study duration needed. 18 
As such, regulatory considerations include the identification of surrogate outcomes for 19 
PTOA studies and the creation of a new indication: OA prevention. This has led to significant 20 
uncertainty for regulatory agencies and drug developers, and has restrained investments by 21 
the pharmaceutical industry.  22 
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An international expert working group was therefore convened with the following aims: to 23 
review the literature on existing interventional studies close to the time of knee injury; give 24 
an overview of key areas in the field relevant to future interventional studies; define 25 
considerations for the conduct and design of trials aimed at prevention of OA; and to 26 
highlight knowledge gaps by developing research recommendations in this area. 27 
Methods 28 
The considerations process was facilitated by the Osteoarthritis and Crystal Diseases Clinical 29 
Studies Group of Arthritis Research UK (UK’s largest arthritis charity), which was established 30 
to develop consensus research priorities and nurture methodologically robust clinical trials.  31 
Whilst preventing joint injury is an intervention to prevent PTOA(7), our focus was on 32 
interventions after knee joint trauma. We conducted an evidence review, then consensus 33 
process developing considerations and a research agenda. Though the evidence review 34 
summarized the use of outcome measures including patient reported outcome measures 35 
(PROMs), no recommendations for specific outcome measures were planned.  36 
Evidence review 37 
An evidence review was conducted to identify experimental, interventional studies 38 
following acute knee injury with specific reference to post-traumatic knee OA. Systematic 39 
searches were conducted across 5 databases (Cochrane 40 
Library;EMBASE;MEDLINE;CINAHLPlus;AMED) from inception to August 2016. The search 41 
strategy was designed in OVID-Medline using text words and subject headings (MeSH), 42 
combining terms for knee injury, osteoarthritis and clinical trials or systematic reviews 43 
(Supplementary Table 1).  44 
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All references were imported into Endnote where duplicates were removed. Screening and 45 
study detail extraction was by NC, verified by 3 others (FW, DM, PC). Study inclusion criteria 46 
were as follows: population clearly stated within 6 months of acute knee injury (any 47 
setting); interventional study (any intervention, including surgical, pharmacological, non-48 
pharmacological) with any comparator (including active, placebo, sham or no intervention); 49 
OA or a surrogate outcome measure; reported randomized controlled trials (RCTs), non-50 
randomized controlled trials or systematic reviews. Study exclusion criteria included: ‘acute’ 51 
injury not clearly separated from ‘chronic’, or from other joint disease; non-English-52 
language articles; letters, comments or editorials. Observational studies of interventions in 53 
this area were not included in our evidence search or considerations, as they were felt to be 54 
prone to bias and not representative of our main focus which related to experimental 55 
studies. 56 
Consensus group  57 
A group of 32 stakeholders, including physiotherapists, orthopedic surgeons, 58 
rheumatologists, sports and exercise medicine physicians, primary care physicians, 59 
radiologists, laboratory scientists, statisticians, clinical trialists, engineers, pharmaceutical 60 
company experts and 4 patient representatives (2 who had a previous knee joint injury) 61 
comprised the consensus group. After the evidence review results were circulated, the 62 
group convened at a face-to-face meeting. The evidence review, which included a summary 63 
on the use of PROMs, was presented and overviews of literature-identified key areas were 64 
given by invited experts: challenges around studies in this area (Lohmander), molecular 65 
biomarkers (Kraus) and imaging (Roemer). Specific case study examples of potential 66 
interventional targets and challenges were presented (Mason, Kraus). Three working groups 67 
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with facilitators and reporters were convened to consider: A: Eligibility criteria and choice of 68 
outcomes, B: The use of biomarkers (including soluble biomarkers and imaging) as potential 69 
stratifiers or outcomes, and C: Definition of the injury, the timing of intervention, and 70 
considerations for multi-modality interventions. Written notes were compiled, presented by 71 
each group’s reporter to all stakeholders and agreement on items and additional 72 
overarching points to consider were generated during a final discussion session, chaired by 73 
PC, with written statements agreed by all (facilitated by FW). The meeting was taped and 74 
transcribed; any uncertainties were addressed from the transcript. Subsequently, the 75 
document and then manuscript was reviewed by all contributors through an iterative online 76 
process.  77 
Results 78 
Evidence Review 79 
The initial search identified 2476 citations (MEDLINE,n=532; EMBASE,n=863; 80 
CINAHLPlus,n=489; AMED,n=60; Cochrane Library,n=532). 945 duplicates were removed. 81 
Screening of the remaining 1531 abstracts yielded 43 eligible studies. Seven systematic 82 
reviews identified a further 15 reported trials. From these 58 papers (including 11 83 
conference abstracts), 37 unique studies were included. Details of each study are 84 
summarized in Supplementary Table 2. The majority of studies involved ACL injury 85 
(n=20;54%), patellar dislocation (n=8;22%) or tibial plateau fracture (n=7;19%), with the 86 
remaining two studies including any ‘acute knee injury’.  87 
Table 1 summarizes the basic study details grouped according to type of injury. All but two 88 
studies were RCTs (n=35;95%). Of 16 studies reporting power calculations, 15 met or 89 
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exceeded the sample size required (Supplementary Table 2). Study duration varied widely, 90 
approximately equally distributed across 0-1 years, >1-5 years and >5 years. Most studies 91 
(70%) compared a surgical intervention against either another surgical or non-surgical/non-92 
pharmacological (henceforth referred to as ‘other’) intervention. Comparisons of post-93 
operative rehabilitation interventions, pharmacological studies (the only studies to use a 94 
placebo arm) and all other interventions each accounted for ~8% of all studies (Table 1). 95 
An overview of inclusion and exclusion criteria for all available full-text papers (n=32) is 96 
shown in Supplementary Table 3. Most studies (88%) had clearly defined eligibility criteria. 97 
Sixty percent provided a specific age range, spanning 13-50 years old. Sex was a specified 98 
criterion in only 3 studies, one of which excluded females. Elite professional sports activity 99 
and pregnancy were exclusions in 20% of studies.  100 
Pre-existing conditions or other concomitant injuries excluded patients in 80% of studies. 101 
For example, previous index (and sometimes contralateral) knee injury and/or surgery were 102 
exclusions in >60% of studies and the presence of OA was an exclusion criterion in 25% of 103 
studies (Supplementary Tables 3&4). 104 
One-hundred-and-forty-seven outcome measures were identified (Table 2), including 105 
physical examination outcomes (n=30), patient-reported outcomes (n=26) of which the 106 
Knee Injury Osteoarthritis Outcome Score (KOOS) was most frequently used (5), imaging 107 
outcomes (n=43), biomarkers (n=39) and other (n=9) (Supplementary Tables 5-9 108 
respectively). Primary outcome measures were identified by only 19 studies (Tables 1&2). 109 
Ten different OA outcomes included 9 imaging structural measures and 1 surrogate 110 
measure, KOOS (Table 2, Supplementary Tables 6&7). Only 5 studies (of ACL rupture 111 
subjects) used molecular biomarkers as outcome measures (Supplementary Table 8). 112 
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Summary of key area discussions 113 
Molecular pathogenesis and biomarkers of the injury response: Recently there has been an 114 
increase in our understanding of the molecular pathogenesis of PTOA. Observations from 115 
both humans and animal models reveal that diverse signaling pathways (involving 116 
inflammation, apoptosis and cell senescence) are activated by injury(9, 10). This activation is 117 
associated with subsequent bone remodeling, cartilage matrix damage and synovial 118 
inflammation(11, 12). Synovial fluid at the time of joint injury shows marked increases in 119 
pro-inflammatory cytokines (e.g. IL-6 is 1000-fold up-regulated) and within 2 weeks shows 120 
evidence of matrix catabolism of both aggrecan and type II collagen(13-15). The response 121 
appears to differ between individuals, and is represented by a tissue inflammatory 122 
response, primarily detectable in the synovial fluid(13, 14, 16). Following injury, a variety of 123 
factors may encourage joint homeostasis and resolution (including normal physiological 124 
loading), or progression to post-traumatic OA (including excessive loading or further injury). 125 
Further injury or surgery would appear to prolong the inflammatory response to 126 
trauma(17). There may be an ‘early therapeutic window’ following joint injury during which 127 
inflammatory response genes are up-regulated and matrix degradation is initiated which 128 
could be targeted by intervention(18). The optimal and/or latest times at which degradation 129 
could be halted or reversed are currently unknown.  130 
Animal models of knee injury: Much work on OA pathogenesis has been accomplished in 131 
animal models, which exploit the association between joint injury and OA, using trauma or 132 
surgically-induced injury to predictably induce disease: they are therefore particularly suited 133 
to testing early interventions in this setting. Findings from murine models such as those 134 
involving destabilization of the medial meniscus appear to translate to human studies of ACL 135 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
7 
 
rupture or meniscal tear(14). The effects of suppressing certain key pathways in these 136 
models have been described in knockout mice(19). Despite this, very few interventions have 137 
been tested at the time of injury, in rodents or in man, as opposed to established OA, which 138 
could account for some of the failure of translation of OA therapeutics to date.  139 
However, there may be some molecular differences as well as some practical challenges in 140 
the testing of intra-articular agents in small animals and in the extrapolation of optimal 141 
timing of an intervention from rodent to man.  142 
 143 
Examples of potential pharmacological targets: Glutamate concentrations are increased in 144 
synovial fluid of arthritic joints in humans and animals, activating glutamate receptors on 145 
neurones and synoviocytes to induce pain and cause release of IL-6(20, 21). Intra-articular 146 
inhibition of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainate 147 
glutamate receptors at the time of injury or induction of arthritis in rodent models alleviates 148 
pain, inflammation and joint degeneration(22, 23). IL-1 causes cartilage degradation in vitro 149 
and is upregulated in synovial fluid following joint injury(24, 25). Blockade of this pathway 150 
(with IL1-receptor antagonist (IL1RA)) reduced inflammation and degeneration in a mouse 151 
model of arthritis(26). IL-1 or AMPA/kainate receptors represent potential therapeutic 152 
targets for preventing later disease, as their inhibition at the time of injury in models of 153 
post-traumatic OA reduced disease. IL1RA is the first therapeutic agent to be tested in 154 
human pilot studies at the time of knee injury for this indication(27). A further example is a 155 
small RCT testing steroid injection within 4 days of ACL tear, where the collagen degradation 156 
biomarker CTX-II was significantly reduced in synovial fluid in the steroid-treated arms(15). 157 
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Since AMPA/kainate receptor antagonists, IL1RA and steroids are already used in man, re-158 
purposing of existing agents is a real possibility.  159 
Imaging in acute injuries: Imaging-based change following knee injury reflects the initial 160 
trauma but also the responses to subsequent changed dynamic knee loading after 161 
destabilizing injuries(28). The majority of studies include X-ray and MRI cartilage outcomes, 162 
both semi-quantitative and quantitative. Although there are a few high-quality longitudinal 163 
imaging studies after ACL rupture, more studies are needed. It is possible to define early OA 164 
on either X-ray or MRI, and evidence indicates that MRI changes alone can act as an 165 
endpoint(29). Depending on the target, non-cartilage MR outcomes, either bone-based, 166 
such as bone marrow lesions (BMLs) or synovitis-effusion, may be appropriate. 167 
Compositional measures using MRI, positron emission tomography (PET) or computed 168 
tomography (CT) remain investigational. Composite metric sequences including T1ρ and T2 169 
have been associated with the PROM KOOS, pain after ACL reconstruction and with synovial 170 
fluid biomarkers at the time of surgery(30-32). Change in these compositional measures 171 
may reflect differences in surgical factors after ACL reconstruction and the pre-injury joint 172 
structure(33).  173 
Consistent changes in cartilage thickness occur after ACL rupture: 2 cartilage regions quickly 174 
increase in thickness over time, whilst other areas decrease(34). Within 3 months of ACL 175 
injury, there are marked changes in knee bone curvature (35). Patellofemoral joint (PFJ) OA 176 
appears more prevalent in cohort studies, particularly relating to ACL 177 
rupture/reconstruction; however, the PFJ is not always examined by X-ray.  178 
Structural changes generally develop slowly, and traumatic and degenerative changes must 179 
be clearly separated, although may appear similar (as in the case of BMLs). Common OA 180 
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assessment semi-quantitative instruments are only partially applicable in this setting: 181 
WORMS, BLOKS and MOAKS do not differentiate between traumatic and degenerative joint 182 
changes, and do not include assessment of post-surgical graft integrity(36). ACLOAS is a new 183 
tool which addresses some of these issues including clear differentiation of traumatic from 184 
degenerative BMLs, extent of baseline traumatic osteochondral damage and assessment of 185 
the graft(37). 186 
Imaging biomarkers predicting OA: A systematic review in this area reported that meniscal 187 
lesions, meniscectomy, BMLs, time from injury and altered biomechanics all are associated 188 
with cartilage loss over time after ACL rupture(38). Greater cartilage damage at baseline is 189 
associated with worse clinical outcome (although this could represent pre-existing OA)(39-190 
41). Presence of cortical depression fractures is associated with a worse International Knee 191 
Documentation Committee (IKDC) score at 1 year(42). MRI-detected inflammation markers 192 
(effusion-synovitis/Hoffa-synovitis) at 2 years after ACL rupture were associated with OA 193 
development at 5 years(43). Effusion, or presence of BMLs at 1 year, or meniscal tears at 194 
any stage were found to be associated with radiological OA at 2 years(39). Early bone 195 
curvature change is predictive of cartilage loss at 5 years and accentuated by the presence 196 
of meniscal injury(35).   197 
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Points to consider 198 
These are summarized under overarching considerations and 3 main areas: eligibility 199 
criteria, outcome measures and definition and timing of interventions and comparators in 200 
these studies. 201 
Overarching considerations: Key overarching considerations are included in Table 3. It was 202 
emphasized that a better understanding of disease pathogenesis was important. The 203 
appropriate time-window, role and effects of a proposed intervention on underlying 204 
processes such as inflammation, mechanical loading and subsequent bone or cartilage 205 
change needs to be elucidated. Some findings may usefully be translated from animal 206 
models; however, it was also noted that there may be important differences between the 207 
response to acute knee trauma and a discrete surgically-induced isolated injury to ACL or 208 
meniscus. It was agreed that the considerations highlighted in this paper should be 209 
reviewed periodically as more data become available, with a maximum of 3 years before the 210 
next revision. 211 
Eligibility criteria: Eligibility criteria should be clearly defined and should identify specific 212 
groups with a modifiable process following their injury in which to test the intervention 213 
(Table 4).  214 
Definition of injury: Examples of well-defined groups based on MRI to be included would be 215 
ACL tear combined with other injuries such as traumatic meniscal tear (although different 216 
outcomes are probably associated with medial or lateral tears(44), or chondral 217 
damage/cortical depression fracture(42). Degenerative meniscal lesions should be 218 
considered part of early OA and not included in acute post-trauma studies(45). 55% of 219 
patients sustain simultaneous injuries to both ACL and meniscus(46); the ubiquitous 220 
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biological response to joint tissues injury supports broader inclusion of injury sub-types. 221 
Combined ligament injuries or fractures should not necessarily be excluded but considered 222 
as a separate ‘extreme’ phenotype, as they may be at substantially increased OA risk, which 223 
may or may not be reversible.  224 
Time since injury: Some interventions may be most effective if exerting their effect as soon 225 
as possible after the early biological changes after injury. The appropriate time window for 226 
any intervention after injury needs to be carefully justified, according to it’s nature.  227 
Age: Those less than 30 years are more likely to have purely traumatic meniscal lesions; 228 
those over age 35 could be at risk of pre-existing OA/degenerative meniscal lesions.  229 
Demographics: Elite athletes are more likely to have past/repeated injuries but may have 230 
different responses to injury compared to non-elite individuals. As elite athletes are at high 231 
risk of OA, they still represent a relevant subgroup for investigation. 232 
Exclusions: Previous substantial knee injury or surgical procedure to the index knee may 233 
confound results and should be considered as a possible exclusion. BMI should be 234 
documented: excessive obesity has independent effects on disease risk, joint loading and 235 
inflammation. 236 
Outcome measures: Key considerations are shown in Table 5. 237 
Patient Reported Outcome Measures: In addition to the collection of longer-term PROMs, 238 
repeated, multiple early measures will allow examination of potential earlier surrogate 239 
endpoints in the future.  240 
Imaging: Baseline and longitudinal evaluation should differentiate pre-existing degenerative 241 
from acute traumatic structural joint damage. The contralateral knee may subsequently be 242 
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affected, therefore differentiating index from control knee is important. Considerations 243 
around type of imaging and its frequency include evidence of specific outcome performance 244 
metrics, feasibility and cost. Where trials are multi-center, MRI protocols need to be 245 
carefully designed (for example, compositional imaging may be challenging in a multi-center 246 
setting, and magnet strength should be considered in the context of ACL reconstruction and 247 
metal artefact). Selection of imaging biomarker (semi-quantitative or quantitative) requires 248 
understanding of the validity, reliability and responsiveness of each measure. MRI 249 
techniques that assess early cartilage changes may be useful. Measures of synovial or fat 250 
pad inflammation may be important for anti-inflammatory therapeutics and MRI techniques 251 
that quantify synovitis may be considered. Early changes in 3D bone shape seen after injury, 252 
which predict subsequent OA warrant further study as a potential surrogate endpoint.  253 
Molecular biomarkers: These were noted to be under development as stratifiers, and as 254 
outcome measures: none were yet sufficiently evidence-based to act as independent 255 
surrogate measures as either an early OA diagnostic, prognostic or patient selection aid for 256 
interventional studies. Irrespective of target, to accelerate therapeutic advances, it is 257 
important that bio-samples be collected in all cohorts and clinical trials where possible. DNA 258 
storage would allow the international community to work collaboratively to identify novel 259 
genetic predictors of outcome. 260 
Synovial fluid was highlighted as a potentially important biosample, showing biologically 261 
important molecular changes after injury and after intervention; synovial fluid molecular 262 
changes are likely to have increased utility compared to serum(13-15). Contralateral 263 
aspiration of synovial fluid was controversial, as the contralateral knee is not always a good 264 
control and it is difficult to aspirate normal joints. It is important that non-surgical studies 265 
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access synovial fluid to avoid bias towards surgical intervention studies. In some cohorts, 266 
serum/plasma/urine may be available prior to the injury (e.g. participants in a biobank or 267 
military cohorts): measuring change within an individual was noted as analytically powerful. 268 
Regarding biomarker choice, the most qualified biomarkers to date, e.g. CTX-II, could be 269 
included if cartilage matrix catabolism is a target; synovial inflammation or bone 270 
biomarkers, or specific cytokine measurements may be relevant depending on target(27).  271 
Functional outcomes: Symptoms of instability could be more reliable than any examination-272 
based measures. However, their sensitivity to change compared with existing measures 273 
such as pain should be evaluated further(47).  274 
Definition and timing of intervention and comparator: The choice of timing of the 275 
intervention will depend on the nature and mode of its action and intended effects, as well 276 
as the measured outcome. An optimal ‘therapeutic window’ should be carefully defined for 277 
any intervention (Table 6), see also Eligibility Criteria: ‘Time Since Injury’. It may be that 278 
identification of high risk phenotypes is possible by imaging or molecular biomarkers at 279 
defined times after the injury. 280 
Types of intervention are highly varied; where multi-modality interventions are used, these 281 
should be carefully defined, and controlled. Drugs could be given systemically or intra-282 
articularly, as single or multiple doses, dependent on agent and duration of treatment, 283 
safety considerations and acceptability. 284 
A comparator and/or placebo or sham arm should be used, because of the known 285 
substantial placebo effect in OA studies(48). The comparator will often be standard or usual 286 
care, rather than no treatment and requires careful definition. Randomization and placebo 287 
control are important principles not only for pharmacological interventions, but also for 288 
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device and surgical studies, where a large placebo effect would be anticipated and which is 289 
not otherwise controlled(49). 290 
There are a number of practical considerations for successful recruitment, randomisation 291 
strategies, the standardisation of the intervention (particularly if surgical) and allocation 292 
concealment in these types of studies, particularly when they are multi-site(18). This  should 293 
be carefully considered during study design and a number of existing OARSI 294 
recommendations in trials of prevention of joint injury and of established OA are highly 295 
relevant here(7, 8, 50, 51). 296 
Research recommendations 297 
The particular challenges and questions highlighted as needing further research are included 298 
in Table 7. 299 
Patient representatives highlighted concerns for the potential for over-diagnosis or 300 
overtreatment in the absence of risk stratification, and further Patient and Public 301 
Involvement is encouraged in this area now, and as the field develops.  302 
Further evidence is needed for which outcomes should be used in this setting, and what 303 
measurement(s) (whether a molecular or imaging biomarker or PROM) might act as an 304 
acceptable surrogate short term outcome for future OA (given that 5-10 year interventional 305 
trials are not feasible). Although these current considerations address interventional 306 
studies, the consensus group acknowledged that ancillary/cohort studies which establish 307 
associations between PROMs, biomarkers and imaging outcomes could address key 308 
knowledge gaps to provide evidence for future trials. The design of these studies should be 309 
carefully considered and outcomes appropriately powered, but they may include more 310 
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exploratory outcomes. Sensitive, specific early measures which might shorten studies 311 
should be sought. 312 
The Consensus group noted that animal studies can inform human studies, and such 313 
programs were justifiable to facilitate early translation of targets to humans. 314 
 315 
Discussion 316 
Our review of the literature has highlighted a lack of conformity in design of interventional 317 
studies in this area.  Evidence from the review and expert consensus has been synthesised 318 
in producing these first international considerations on the design and conduct of 319 
interventional studies aiming at prevention of OA following acute knee injury. Critical 320 
knowledge gaps limiting such trials have been highlighted, and summarised as research 321 
recommendations. These considerations are intended to underpin future guidelines as this 322 
field evolves. Collaborative working on cohort and feasibility studies is needed to provide 323 
better evidence for interventional study design.  324 
Studies need to include those patients who are at the highest risk, but whose risk is 325 
modifiable by the proposed intervention. There was an awareness of the identity of 326 
extreme phenotypes, such as combined ligament injuries, which may fall outside these 327 
criteria. As in OA, predictive risk modelling is needed for knee trauma(52). A better 328 
understanding of underlying disease mechanisms from both animal and human studies is 329 
needed. Understanding how related mechanisms such as inflammation and mechanical 330 
loading of the joint after trauma contribute to either resolution or progression to OA was 331 
deemed essential for the development of new interventions. 332 
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The feasibility and acceptability of testing interventions in an acute setting can be 333 
challenging. Informed consent for sham or placebo treatments at the time of knee injury 334 
needs careful review by patients, healthcare providers and trialists. Sham-controlled trials 335 
including surgical trials are often needed to provide the best possible level of evidence(49). 336 
Recent consensus in classification of early knee OA will facilitate such trials(53). Alternative 337 
surrogate outcome measures need to be developed to shorten trial duration and improve 338 
the likelihood of drugs being developed by industry. MRI costs are relatively high, but may 339 
be justified by allowing researchers to examine earlier outcomes. Whilst X-ray follow-up 340 
may appear more feasible, it’s use as a lone imaging modality must be adequately powered. 341 
There are some limitations to the approach used. The literature review was performed to 342 
provide evidence for discussions, rather than as a stand-alone piece of work; it was clear 343 
after the initial search that areas of interest, such as pharmacological interventions, were 344 
not well represented in the current literature, and limitations of generalizability to all types 345 
of interventions should therefore be borne in mind. A critical appraisal of the studies was 346 
not performed as it was not felt necessary for the requirements of this review, which was 347 
pragmatic in nature. Given the relatively low number of RCTs identified in this area, non-348 
randomized controlled trials as well as RCTs were included where identified. Not all opinions 349 
might be equally represented from this type of approach. However, a wide range of 350 
stakeholders and groups were involved, including patients. Effort was made to ensure 351 
diversity; pre-appointed facilitators and reporters with note-keeping and voice recording of 352 
sessions ensured a transparent and consistent process. More detailed discussions on 353 
considerations of recruitment/randomization/allocation concealment strategies were 354 
beyond our scope(54). 355 
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In summary, these initial considerations provide a starting point for further work in this 356 
area. These points are intended to be complimentary to, and should be considered 357 
alongside, OARSI Clinical Trials Recommendations on prevention of joint injury, the design, 358 
analysis and reporting of OA RCTs and clinical requirements for development of 359 
therapeutics in OA(7, 50, 51, 55). The regulatory considerations for a new indication of 360 
preventing symptoms or OA structural change following joint injury are unique. Engagement 361 
with both regulators and the pharmaceutical industry is essential if the area is to progress 362 
and overcome current hurdles. Although such trial designs may be challenging, in order to 363 
develop new therapeutics with the aim of patient benefit, the consensus was that progress 364 
in this area is both possible and urgently required.   365 
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Table 1. Overview of basic study details, categorized according to type of knee injury.  591 
 592 
 ACL 
Patellar 
Dislocation 
Tibial plateau 
fracture 
Other Total 
Number of studies 
[papers if different] 
20 [40 papers 
incl. 11 conf. 
abstracts] 
8 [9 papers, 
incl. 1 
abstract only] 
7 incl. 2 
abstract only 
2 studies 
37 [58 papers 
incl. 11 conf. 
abstracts & 3 
abstracts only] 
RCT/nRCT 
RCT: 20 incl. 1 
protocol and 1 
pilot 
RCT: 7 
nRCT: 1 
RCT: 6 incl. 1 
protocol  
nRCT: 1 
RCT: 2 incl. 
1 pilot 
RCT: 35 incl. 2 
pilots, 2 
protocol; nRCT: 2 
Sample size at 
randomization 
   
Missing 1    1 
<20 2   1 3 
20-50 5 5 4  14 
>50-100 7 2 2  11 
>100-200 5 1 1 1 8 
Power calculation      
a priori 9 5 2  16 
post hoc 2   1 3 
None 8 2 3 1 14 
Unclear 1 1 2  4 
Study adequately 
powered (based on 
sample size) 
9 of 9 4 of 5 2 of 2  15 of 16 
Study duration    
Missing  1 1  2 
<3 months 1   1 2 
3 - 6 month 3    3 
>6 months – 1 year 3  3 1 7 
>1 – 2 years 4 3   7 
>2 – 5 years 3  2  5 
>5 – 10 years 2 3   5 
>10 years 4 1 1  6 
Primary outcome 
measure(s) clearly 
defined 
9 + 1 used for 
sample size 
calculation 
5 
2 + 1 used for 
sample size 
calculation 
1 
17 + 2 based on 
sample size 
calculation 
Type of interventions    
Surgical vs Surgical 10  7  17 
Surgical vs Other 1 8   9 
Other vs Other 3    3 
Pharmacological vs 
Pharmacological 
2 (all placebo)   1 (placebo) 
3 all placebo 
controlled 
Post-op Rehab vs Post-
op Rehab 
2   1 3 
Post-op Pharma vs 
Post-op Pharma 
1    1 
Post-op Pharma vs No 
intervention 
1    1 
ACL – Anterior cruciate ligament 593 
RCT Randomized controlled trial 594 
nRCT=non-randomized controlled trial  595 
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Table 2: Summary of outcome measures.  596 
Outcome 
measure 
category (n*) 
Primary outcomes Osteoarthritis and surrogate OA outcomes 
Physical 
examination 
n  = 30 
1. Laxity (n = 4)  
2. Patellofemoral stability (n = 2) 
3. Limb symmetry indices (n = 1) 
4. Torque (n = 1) 
5. Muscle electrical activity (n = 1) 
6. Functional – hop test (n = 1) 
Patient reported 
n  = 26 
1. Knee injury Osteoarthritis Outcome 
Score (KOOS) (n = 5) 
1. Knee injury Osteoarthritis Outcome 
Score (KOOS) (n = 1) 
2. Hospital for Special Surgery (HSS) knee 
score (n = 2) 
3. International Knee Documentation 
Committee (IKDC) Subjective Knee 
Form (n = 2) 
4. Kujala score (n = 2) 
5. The Knee Self-Efficacy Scale (K-SES) (n 
= 1) 
6. The Physical Activity Scale (n = 1) 
7. Tegner activity score (n = 1) 
8. Multidimensional Health Locus of 
Control (n = 1) 
Imaging 
n  = 43 
1. Radiographic: Kellgren-Lawrence 
classification (n = 1) 
1. Radiographic: Study specified criteria 
incl. joint space narrowing, osteophyte 
grade, subchondral sclerosis and 
sharpening of tibial spines (n = 4) 
2. CT: Quality of reduction (n = 1) 2. Radiographic: Kellgren-Lawrence 
classification (n = 4) 
3. MRI: Morphologic measures of 
articulating bone curvature (femur, 
tibia & trochlea) (n = 1) 
3. Radiographic: Ahlbäck classification (n = 
2) 
4. MRI: Cartilage thickness of 
femorotibial medial compartment (n = 
1) 
4. Radiographic: modified OARSI grading 
scale for OA (n =1) 
5. MRI: Anterior Cruciate Ligament 
Osteoarthritis Score (ACLOS) (n = 1) 
5. Radiographic: Medial joint space width 
(n = 1) 
6. Radiographic: Ahlbäck & Fairbank 
composite scale (n = 1) 
7. MRI: Whole Organ Magnetic Resonance 
Imaging Score (WORMS) (n= 1) 
8. MRI: Anterior Cruciate Ligament 
Osteoarthritis Score (ACLOAS) (n = 1) 
9. qMRI: Early matrix changes typical of 
arthritis (n = 1) 
Biomarkers (n 
=39) 
1. GAG/proteoglycan marker: ARGS-
aggrecan (n = 1) 
 
Other (n = 9) 2. Safety, tolerability & adverse effects (n = 
1) 
 
TOTAL  n  = 147 Total = 21 primary outcomes Total = 10 measures 
 597 
 598 
*where n=total number of studies with such measures   599 
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Table 3: Recommendations for points to consider: overarching considerations 600 
Consideration Recommendation 
1. General 
  Considerations should be relevant to the design of all forms of 
interventional study following joint injury, unless otherwise 
stated 
  CONSORT or STROBE criteria should be adopted in the design 
and reporting of any interventional or cohort study in this area 
  Patients and the public should be involved throughout the 
process of study design and delivery  
 
2. Regulatory 
  Current and future regulatory considerations and requirements 
in this area should be considered in design of future studies 
  The community should work closely with regulatory bodies to 
establish evidence and precedent for outcomes and design of 
interventional trials 
  Responder criteria, the number needed to treat for benefit 
(NNT), and cost-effectiveness should be measured 
3. Feasibility 
  Feasibility, patient burden and cost considerations of, for 
example, type of imaging, or intervening near to the injury 
should be carefully weighed against the scientific/therapeutic 
benefits of the proposed approach 
  For any given study, a balance should be found between 
scientific rigor in design and pragmatic considerations regarding 
recruitment and generalizability to clinical practice 
4. Specific targets 
  Some of the considerations around study design (including 
eligibility criteria, outcomes and time-window of intervention) 
may be different, depending on the nature of the intervention 
  There may be particular biomarker(s) which are specific and 
sensitive for a particular intervention 
 
5. Stratification 
  The assessment of personal or individualized risk was noted to 
be important 
  Novel molecular or imaging biomarkers might be used in the 
future as stratifiers at the point of entry to the study, or as 
intermediate (surrogate) outcomes, but none are validated for 
these purposes currently 
  Effective stratification of an individual’s personal risk of post-
traumatic OA is not yet possible based on current knowledge 
  601 
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Table 4: Recommendations for points to consider: eligibility criteria 602 
Consideration Recommendation 
1. Definition of acute knee injury 
  The extent and characteristics of acute structural 
joint damage should be fully classified by magnetic 
resonance imaging 
  Subgroups/types of injury for inclusion such as ACL 
and/or meniscal tear should be carefully defined 
  Different types of injury may be associated with 
different biomechanical outcomes and 
responsiveness to any given intervention, so the 
target population needs to be carefully defined 
  In the case of meniscal tears, the individual’s age, 
history of a clear injurious episode, plus MR 
appearances are all important in identifying 
traumatic tears (and excluding degenerative lesions 
from these studies) 
  Caution should be exercised in the inclusion of 
extreme phenotypes, for example those with 
isolated ACL tears or very extensive injuries 
2. Time since injury 
  Establishing an appropriate therapeutic time-
window will be relevant for each new 
target/intervention 
  Certain interventions targeting the early response to 
injury may benefit from being tested within days of 
injury, or up to a maximum of 4-6 weeks from injury 
3. Age 
  Upper age limit should be carefully considered; an 
upper age limit of 35 was proposed 
  Challenges were highlighted around intervening in 
pediatric populations who lack capacity to give 
informed consent or who have immature growth 
plates 
 
4. Demographics 
  People of both sexes should be included 
  Studies may include, but should not be restricted, to 
professional athletes 
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5. Proposed exclusions 
  Other existing causes of joint pathology 
o inflammatory arthritis or pre-existing 
established osteoarthritis 
o other disorders of bone, current or past 
o previous substantial injury or surgery of 
index knee (particularly where there would be 
an associated markedly increased risk of PTOA) 
o other concomitant body injury or surgery 
(in some circumstances as may confound 
biomarkers) 
  Pregnancy or breast-feeding 
  Heavy use of alcohol, or recreational drug use  
  Morbid obesity 
 603 
  604 
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Table 5. Recommendations for points to consider: outcome measures 605 
Consideration Recommendation 
1. General 
  Measures of symptoms and structure are both important and 
should be recorded 
  The primary outcome measure(s) are likely to be required 
after 1-2 years after intervention but should relate to the 
study question 
  Short, medium and long term outcomes should be collected 
  Frequent outcomes should be considered in the first year, 
particularly for efficacy and biomarker-related questions 
2. Patient reported 
outcomes measures 
(PROMs) 
  PROMs which have been validated within appropriate 
populations and which examine pain, function, performance 
and quality of life were recommended  
  The choice of tool should depend on its extent of validation 
and reliability as well as feasibility including cost 
  Early assessment of the cost effectiveness of any given 
intervention, or interventions should be considered 
 
3. Imaging 
  Imaging should be used a) to categorize and phenotype, and 
b) as an important outcome measure 
  MRI and X-ray are both important outcome measures, but 
MRI may have increased sensitivity at earlier times after 
injury 
  The patello-femoral joint and tibio-femoral joints should both 
be included in imaging assessments 
  An index/signal knee should be defined (given that the 
opposite side may subsequently be affected) 
   The contralateral knee may be a useful imaging control or 
comparator for the index/signal knee 
   The index/signal knee, and ideally both knees, should be 
imaged at 0 (baseline), 12 months and 24 months for 
structural changes after intervention; inclusion of a later time 
point, such as 5 years was also recommended 
  Morphology and change in all joint tissues should be 
captured, using validated semi-quantitative and/or 
quantitative measures 
  Compositional assessment at 6 months for cartilage (MRI) or 
bone changes (MRI, PET, CT) is more experimental but should 
be considered in addition to structural assessments 
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4. Molecular biomarkers 
  No specific biomarker(s) can be recommended for routine use 
in interventional studies 
o Biomarkers cannot yet act as independent surrogate 
endpoints for early OA diagnosis  
o Biomarkers have not been validated for aiding 
selection of patients for interventional studies 
  Molecular biomarkers should be considered as exploratory 
outcome measures in interventional studies 
o Choice(s) will depend on the target and outcomes 
under study 
  Bio-samples (including synovial fluid, in addition to 
serum/plasma and urine) should be collected in all future 
studies where possible 
o Serum and urine should be collected at all available 
time points 
o Sampling should include DNA storage where 
appropriate consent is given 
o Synovial fluid can be accessed at the time of surgery 
or clinical aspiration, or at the time of drug delivery 
into the index/signal knee 
o Timing and method of sample collection must be 
consistent and standardized across all studied patients 
5. Functional outcomes 
  Stability of the knee and muscle strength are important to 
patients, and potentially important outcome measures 
  Symptoms of instability may have value in addition to 
examination-based measures of mechanical instability/laxity  
  Other potential functional biomarkers include kinematics, hop 
or stair climbing tests and muscle co-contraction testing 
  606 
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Table 6. Recommendations for points to consider: definition and timing of intervention and 607 
comparators  608 
Consideration Recommendation 
1. General 
  Optimal time-window for administration of any given 
intervention should be validated and clearly defined  
  Assumptions should be avoided; different proposed time-
windows for intervention should be tested head to head in 
feasibility studies if necessary, to ensure patient acceptability, 
recruitment and likely translation in to clinical care 
2. Comparators 
  A comparator and/or placebo or sham arm should always be 
used where possible 
o Choice will depend on whether study is efficacy or 
pragmatic  
o Patients should be randomized to intervention or 
comparator arms 
o Assessment of acceptability of sham treatments, 
particularly when invasive, is paramount when 
considering design and feasibility 
  Double blind protocols should be used where possible 
  While double-blinding is not always possible, blinded 
observer/assessor almost always is 
3. Multimodality intervention 
  Multi-modality interventions may be particularly suited to this 
area 
o Such studies are very challenging to design and deliver 
and require expert input 
o Choice of each component ideally requires a priori 
evidence of effect 
  The interaction of different interventions is an important 
consideration in this area, given that multi-modal 
intervention is common in clinical practice.  
 609 
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Table 7. Research recommendations 611 
 612 
Consideration Recommendation 
1. General 
  To best define populations to be included in studies, further 
work is needed to understand relative risk of OA in different 
injury types, identifying 
o Injuries which are easily defined and categorized and 
are at high risk of OA  
o Injuries for whom this risk is likely to be reversible 
o Injuries particularly suited to different types of 
intervention 
  Further work to enable prediction/stratification of individual 
risk of future OA at the time of injury, using clinical factors 
imaging and/ or molecular biomarker profiling is needed 
o These predictors should be examined alone but also in 
combination 
  Further work on defining the appropriate time-window for 
intervention after joint injury is needed 
o This may differ depending on the nature of the 
proposed intervention and the population studied 
2. Pre-clinical studies 
 
  The analogous nature of animal models of post-traumatic OA 
was highlighted, and the potential to therefore support 
translational interventional studies in human  
  Animal models or experimental medicine studies in human 
should be used to define the likely best delivery of an 
intervention, its optimal time-window and initial 
pharmacokinetics, to support future clinical trials 
 
3. Preparation for translation 
 
 
 
 
 
   Patient and public involvement should be sought, particularly 
around areas of assessing risk of disease, risk of harm, risk of 
overtreatment and acceptability of different types of 
proposed interventions 
  Feasibility studies are encouraged to address questions 
specific to an intervention, acceptability to patients, and 
refine best outcomes. Findings should be published, to enable 
shared knowledge. 
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4. Outcomes 
  Better evidence for the modality and timing of early imaging 
as an outcome measure is needed 
  Evidence to support the use of surrogate outcomes of efficacy 
is needed: clinical/PROMs-based, imaging-based or 
biomarker-based, linking these early outcomes to later 
disease risk 
  Evidence for the recommendation of one or more PROMs 
with the best utility in this area should be sought 
  Longer observational/cohort/clinical trials should be designed 
to collect information on: 
o natural history of joint trauma and outcomes 
o utility of molecular biomarkers  
o relationship between PROMs, biomarkers and imaging 
outcomes 
o relationship between early outcomes (at 1 or 2 years) 
and later outcomes at 5-10 years 
  Close liaison with industry and with regulatory authorities on 
the areas of outcomes research and clinical need is advised to 
achieve an indication in this area  
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